ARIA
Library/hormonal/GHRP-2

GHRP-2

Not FDA Approved⛔ WADA Banned

Growth Hormone Releasing Peptide-2 / KP-102

hormonal◆EmergingGrowth hormone secretagogue / Ghrelin receptor agonist

Synthetic hexapeptide growth hormone secretagogue. Potent GH release stimulator — more potent than GHRP-6 in GH release but with moderate appetite stimulation. Does not significantly elevate cortisol or prolactin. WADA banned. Used in GH deficiency diagnosis and off-label for anti-aging.

Confidence
50%
Half-Life ~30 minutes
Cost ~$200/mo
Quick Reference
Routesubcutaneous / intranasal
MechanismSelective agonist at GHS-R1a (ghrelin receptor) on pituitary somatotrophs and hy...
SequenceD-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Mol. Weight817.96 Da
Reviewed2026-08-08

Mechanism of Action

Selective agonist at GHS-R1a (ghrelin receptor) on pituitary somatotrophs and hypothalamic arcuate nucleus → stimulates GH release. Activates Gq/11 → PLC → IP3/DAG → Ca2+ release → GH exocytosis. Minimal effect on cortisol/prolactin (unlike GHRP-6). Moderate appetite stimulation via hypothalamic NPY/AgRP neurons.

Dosing Protocol

100-300μg SC, 1-3x daily (fasting). Intranasal: 100-300μg TID. Cycle 3-6 months on, 1-3 months off. Often paired with CJC-1295 for synergistic GH pulse.

Key Studies

1997

GHRP-2: potent GH release in humans

PMID 9349645clinical_trial
1999

GHRP-2 GH response in GH-deficient adults

PMID 10386498clinical_trial
2015

GHRP metabolites in doping analysis

PMID 25869809analytical

Adverse Effects

FlushingIncreased appetiteWater retentionInjection site reactionsTransient cortisol elevation (mild)Carpal tunnel (with prolonged use)

Contraindications

  • Active malignancy
  • Pregnancy
  • Competitive athletes (WADA banned)
  • Diabetic retinopathy
  • Closed epiphyses

Storage

Lyophilized: 2-8°C or frozen. Reconstituted: 2-8°C, use within 30 days. Bacteriostatic water recommended.

Clinical Applications

  • ["hormonal_optimization"
  • "gh_deficiency"
  • "anti_aging"
  • "body_composition"]